| abstract |
Disclosed is a method for treating or preventing ophthalmic diseases comprising administering one or more aldosterone receptor antagonists containing a 9,11-epoxy moiety, such as eplerenone. The method results in a reduction in intraocular pressure that treats or prevents eye disease. Among the diseases are hypertonia, glaucoma, hypotonic glaucoma, aging-related macular degeneration (AMD), macular edema and diabetic retinopathy. Glucocorticoids and mineralocorticoids also cause retention of ions such as sodium and potassium, so aldosterone receptors are positioned and aldosterone receptor antagonists containing 9,11-epoxy moieties, such as eplerenone, are also ionic eyes. Can be administered to modulate the internal concentration. Thus, aldosterone receptor antagonists can be administered to maintain an intraocular ionic environment that is beneficial to ocular cell survival. |